REVIEW

Ocular toxicity of biological therapy in solid tumors

 Toxicitatea oculară a terapiilor biologice în tumorile solide

First published: 13 decembrie 2022

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/OnHe.61.4.2022.7416

Abstract

With more than 10 million deaths per year, cancer is the main cause of mortality in the world. The traditional non­sur­gi­cal treatments, chemotherapy and radiotherapy, are as­so­cia­ted with high morbidity rates, acting nonspecifically on all cell types, including the healthy ones. This is the rea­son why, in the past 20 years, novel anticancer biological the­ra­pies have emerged. By stimulating the body’s own im­mune system to fight against cancer cells, interfering with progression and tumor growth, these drugs target the can­ce­rous cells only, the impact on normal tissues being mi­ni­mal. Biological therapy has thus become an important com­po­nent of systemic treatment in a large range of tu­mors. Despite the targeted mechanism, numerous side ef­fects of biological therapy have been described, mainly re­gar­ding the digestive system, liver, skin, central nervous and cardiovascular system. There are few studies regarding the ocular side effects of these treatments. The main ocular patho­logies associated with biological therapy are dry eye syn­drome (1-24%), uveitis (1%) and myasthenia gravis with ex­tra­ocu­lar muscle involvement. Although rare (1%), ocular side effects can have serious consequences on the quality of life and can influence the patient’s compliance with sys­temic therapy. Furthermore, we must keep in mind that, as biological therapies become more widely used, the side ef­fects will be more frequently encountered and reported. In Ro­ma­nia, there are no centralized data regarding the ocular side effects determined by cancer treatments in general or by bio­lo­gi­cal therapies in solid tumors in particular, especially since it is a newly introduced therapeutic option in current prac­tice. Based on the relevant data from the specialized li­­te­ra­ture, we want to highlight the most frequent ocular side effects, establish an ophthalmological follow-up pro­to­col for the cancer patient according to the frequency, but also the time of appearance of eye pathologies, as well as to improve the therapeutic protocol for eye conditions in patients undergoing systemic anticancer treatment in Romania.

Keywords
cancer, novel therapies, side effects, eye

Rezumat

Cancerul este principala cauză de mortalitate în lume, cu peste 10 milioane de decese anual. Tratamentele medicale clasice, chi­mioterapia şi radioterapia, asociază o morbiditate crescută, prin acţiunea nespecifică asupra tuturor tipurilor celulare, in­clu­siv asupra ţesuturilor sănătoase. Acesta este motivul pen­tru care în ultimii 20 de ani s-au dezvoltat medicamente ce vi­zea­ză specific creşterea şi supravieţuirea celulelor tumorale prin stimularea sistemului imunitar al pacientului şi prin in­du­ce­rea unui proces autoimun endogen capabil să elimine ce­lu­le­le canceroase sau să influenţeze creşterea şi progresia tu­mo­ra­lă. Terapia biologică a devenit astfel o componentă im­por­tan­tă a tratamentului sistemic într-o gamă variată de tumori. Cu toate că afectarea ţesuturilor nontumorale este minimă, s-au descris numeroase efecte secundare ale te­ra­piei biologice, în principal la nivelul sistemului digestiv, fi­ca­tu­lui, pielii, sistemului nervos central sau cardiovascular. Exis­tă puţine studii care descriu efectele secundare oculare ale aces­tor tratamente. Principalele patologii oculare asociate cu terapia biologică sunt reprezentate de sindromul de ochi us­cat (1-24%), uveitele (1%) şi miastenia gravis cu implicarea muş­chi­lor extraoculari. Deşi rare (1%), efectele adverse oculare pot avea consecinţe grave asupra calităţii vieţii şi pot influenţa com­pli­an­ţa pacientului la terapia sistemică. În plus, trebuie să ţinem cont că, pe măsură ce terapiile biologice vor fi din ce în ce mai folosite, şi efectele secundare vor fi mai des întâlnite şi raportate. În România nu există date centralizate cu privire la afectarea oculară determinată de tratamentele oncologice în general sau de tratamentul biologic în tumorile solide în spe­cial, cu atât mai mult cu cât este o variantă terapeutică nou in­tro­du­să în practica curentă. Bazându-ne pe datele relevante din literatura de specialitate, dorim să evidenţiem cele mai frec­ven­te efecte secundare oculare, alături de stabilirea unui pro­to­col de urmărire oftalmologică a pacientului oncologic, în func­ţie de frecvenţa, dar şi de momentul apariţiei afecţiunilor of­tal­mo­lo­gi­ce, precum şi îmbunătăţirea protocolului terapeutic al afecţiunilor oculare la pacienţii aflaţi în tratament oncologic sis­te­mic în România.

Introduction

With more than 10 million deaths per year, cancer is the main cause of mortality in the developed countries(1). Beside surgery, chemotherapy and radiotherapy are the classic nonsurgical available options in the fight with this horrible disease. Unfortunately, these treatments associate high morbidity, acting nonspecifically on all cell types, including healthy tissues(2). This is the reason why, in the past 20 years, novel anticancer biological therapies have emerged. These drugs target the cancerous cells only, the impact on normal tissues being minimal(3). Through specific molecules or antibodies, biological therapy stimulates the body’s own immune system to fight against cancer cells, interfering with progression and tumor growth(3,4).

Despite the targeted mechanism, numerous side effects of biological therapy have been described, mainly regarding the digestive system, liver, skin, central nervous and cardiovascular system(5). Regarding the eye, there are very few studies on a small number of patients and do not really focus on ophthalmic side effects.

The eye is a complex structure that includes blood vessels, nerve fibers, muscles and skin. The toxic side effects of biological treatments can be found at the level of the orbit, eyelids and eyeball (from the corneo-conjunctival level to the level of the retina and optic nerve)(6). Also, we must not forget that the eye is an extension of the brain, so any cerebral side effect can affect the visual cortex or the optical pathways.

The main ocular side effects of novel anticancer biological therapies are dry eye syndrome (1-24%), uveitis (1%), and myasthenia gravis with extraocular muscle involvement(7).

Although rare (1%), the ocular side effects can have serious consequences on the quality of life and can influence the patient’s compliance with systemic therapy(8). In addition, we must keep in mind that, as biological therapies will be more and more used, side effects will be encountered and reported more frequently(9).

Biological agents

The main classes of biological agents approved by the Food and Drug Administration (FDA) and by the Euro­pean Medicines Agency (EMA), also available in Romania, associated with ocular side effects, are: epidermal growth factor receptor inhibitors, vascular endothelial growth factor receptor inhibitors, inhibitors of specific proteins, estrogen receptor modulators, and interferons(9).

Epidermal growth factor receptor inhibitors are used to treat multiple solid tumors, mainly carcinomas – of the lung, pancreatic, colorectal, or basal cell carcinoma(10). The epidermal growth factor receptor is one of the key receptors in corneal regeneration, being expressed mainly in the corneal epithelium and endothelium(11). In the event of a corneal injury, the epidermal growth factor receptor is increasingly expressed and epithelial cells migrate to the affected area. The migrated cells also express epidermal growth factor receptors and proliferate by binding epidermal growth factor(12), which is mainly present in the tear film(13). Thus, by inhibiting the epidermal growth factor receptor, healing of the corneal epithelial defects is delayed(14), and in extreme cases it can lead to corneal perforation(10). Epidermal growth factor also stimulates the proliferation of epithelial cells at the level of the palpebral meibomian glands – so, inhibiting its effect, causes meibomitis(15). Since the epidermal growth factor receptor is also expressed in the hair follicle, its inhibition may cause trichomegaly or trichiasis(15). Studies have shown that the occurrence of side effects is dose-dependent: the higher the dose, the higher the risk of developing complications(16). Other oculopalpebral side effects associated with epidermal growth factor receptor inhibitors are blepharitis, conjunctivitis or dry eye syndrome(10). The patients complain of swollen, red eyelids, conjunctival hyperemia, or foreign body sensations. The use of artificial tears at least four times a day in patients who receive epidermal growth factor receptor inhibitors is proven to be useful as a prophylactic method(9).

Vascular growth factor receptor inhibitors are used for the treatment of renal cell carcinomas or gastrointestinal stromal tumors. Bevacizumab is a monoclonal antibody used for the treatment of colorectal carcinoma. It can cause cerebral vasospasm and a partially reversible posterior leukoencephalic syndrome, clinically manifested by cortical blindness(17). For more than 10 years, bevacizumab has been also used in ophthalmology, off-label, through intravitreal injections, for the treatment of vascular occlusive disorders and age-related macular degeneration.

Crizotinib is an anaplastic lymphoma kinase inhibitor, a tyrosine kinase, used for the treatment of non-small cell lung cancer. Ocular damage may occur as early as two weeks after the initiation of treatment(18). The main side effects are photopsia and myodesopsia(18), which are considered minor by the FDA.

Immune checkpoint inhibitors are used in the treatment of lung cancer both in early and late stages. The main immune checkpoint inhibitors are CTLA-4 (cytotoxic T lymphocyte antigen 4) inhibitors, PD-1 (programmed cell death protein 1) inhibitors and PD-L1 (programmed death-ligand 1) inhibitors. They “unlock” the immune checkpoints intended to prevent autoimmune phenomena, but this state of hyperreactivity of the nonspecific immune system causes unwanted effects. The most frequent side effects of this type of biological therapy are ophthalmoplegia (40.51%), uveitis (20.25%) and dry eye syndrome (17.72%)(19). Other immune-related side effects are conjunctivitis, corneal ulcers with perforations, corneal graft rejection, optic neuritis, retinopathy, amaurosis fugax, orbital inflammation, and giant-cell arteritis(19). Ipilimumab is a human monoclonal antibody used for the treatment of metastatic malignant melanoma. At approximately 6-12 weeks after the beginning of the treatment, pituitary gland changes may occur, mimicking Graves’ ophthalmopathy, with proptosis, extraocular muscle edema, dry eye syndrome, all most likely due to CTLA-4 receptor polymorphism(20). Side effects are remitted under systemic steroid treatment that do not reduce the effectiveness of ipilimumab therapy, but doses must be gradually reduced over several weeks, as sudden discontinuation causes symptoms to recur(21). Another rare side effect associated with ipilimumab is iridocyclitis, through an immune cross-reaction with the iris pigment epithelium(22). These patients complain of floaters and visual loss(22).

Tamoxifen is a selective estrogen receptor modulator used as an adjuvant therapy for breast cancer. The frequency of ocular side effects was reported to be between 0.6% and 12%(23). The most common side effects are crystalline retinopathy (which do not usually cause visual disturbances), macular edema and macular hole that can lead to significant vision loss(23).

Interferons are associated with multiple serious ocular side effects. Interferon-induced ischemic retino­pathy can occur after approximately three months of treatment and affects more than 40% of patients(24). Typical changes are retinal hemorrhages and cotton-wool spots as a sign of nerve fiber edema. Anterior ischemic optic neuropathy was also reported in 36 patients and in 60% of cases the involvement was bilateral(25). Patients suffered visual field amputations or dra­matic vision loss, reversible in only 50% of cases(25) after the discontinuation of interferon therapy. Myasthenia gravis, manifested mainly by diplopia, may also develop during interferon therapy(26).

Methodology

Patients diagnosed with solid tumors at the “Dr. Carol Davila” Clinical Hospital of Nephrology, Bucharest, between January 2023 and January 2024, will be recruited to participate in this prospective observational clinical trial. The purpose is to identify structural and functional ocular changes associated with the biological therapy. The patients will be divided into two groups: patients newly diagnosed with cancer, who did not undergo any systemic cancer treatment before entering the study, and patients who have undergone cancer treatments before entering the study, in which biological therapy has an adjuvant role. All the patients will undergo a full eye examination before the biological treatment and all the systemic comorbidities will be noted. According to the latest research, most ocular side effects appear in the first three months after the initiation of treatment, so we will examine patients monthly in the first six months, then every three months in the first year. Hopefully, we will highlight the most frequent eye side effects, establish an ophthalmological follow-up protocol for the cancer patient according to the frequency, but also on the time of appearance of eye pathologies, as well as improve the therapeutic protocol for eye conditions in patients undergoing systemic anticancer treatment in Romania.

Discussion

Novel anticancer biological therapies represent the main future direction for the treatment of cancer patients. However, they are new therapies, whose mechanisms of action are not fully understood. Some molecules have a well-defined safety profile, while others are newly introduced into practice, and it takes time and vigilance in reporting adverse effects. There is always the risk that side effects are not observed, especially since cancer therapies frequently associate several different molecules within treatment protocols, which causes difficulties in establishing etiological connections(9). Since the ophthalmologist cannot say whether the symptoms are caused by one particular molecule, by its association with another, or if the side effects occur only when the combined molecules target various signaling pathways, the recognition and treatment of ocular complications require a close collaboration between the oncologist and the ophthalmologist. If the side effects are serious, the therapeutic doses will be reduced. If the symptoms do not improve or get worse, the biological treatment needs to be stopped(9).

Conclusions

Ocular side effects of anticancer biological therapies are important.  Depending on the type of the molecule used(9), they can occur in up to 70% of cases, which is precisely why periodic eye and vision examinations of patients undergoing biological oncological treatment are necessary.  

 

Conflicts of interests: The authors declare no conflict of interests.

 

Bibliografie

  1. World Health Organization: Regional Office for Europe. World Cancer Report: cancer research for cancer development (IARC, 2020).

  2. Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother. 2009;58(3):317-324.

  3. Tsimberidou AM, Eggermont AM, Schilsky RL. Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 2014;61-69.

  4. Li Y, Liu S, Margolin K, Hwu P. Summary of the primer on tumor immunology and the biological therapy of cancer. J Transl Med. 2009;7:11.

  5. Kroschinsky F, Stölzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21(1):89.

  6. Abdel-Rahman O, Oweira H, Petrausch U, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther. 2017;17(4):387-394.

  7. Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol. 2016;28(4):288-294.

  8. Hazin R, Abuzetun JY, Daoud YJ, Abu-Khalaf MM. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients. Curr Opin Ophthalmol. 2009;20(4):308-317.

  9. Hager T, Seitz B. Ocular side effects of biological agents in oncology: what should the clinician be aware of?. Onco Targets Ther. 2013;7:69-77.

  10. Saint-Jean A, Sainz de la Maza M, Morral M, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology. 2012;119(9):1798–1802. 

  11.  Klenkler B, Sheardown H. Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. Exp Eye Res. 2004;79(5):677–688. 

  12. Xu KP, Ding Y, Ling J, Dong Z, Yu FS. Wound-induced HB-EGF ectodomain shedding and EGFR activation in corneal epithelial cells. Invest Ophthalmol Vis Sci. 2004;45(3):813–820.

  13.  Enríquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis. 2010;16:862–873. 

  14.  Nakamura Y, Sotozono C, Kinoshita S. The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res. 2001;72(5):511–517. 

  15. Fraunfelder FT, Fraunfelder FW. Trichomegaly and other external eye side effects associated with epidermal growth factor. Cutan Ocul Toxicol. 2012;31(3):195–197.

  16.  Fabbrocini G, Panariello L, Cacciapuoti S, Bianca D, Ayala F. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases. Dermatitis. 2012;23(5):237–238.

  17. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354(9):980–982.

  18. Pfizer Labs. Food and Drug Administration: Highlights of Prescribing Information XALKORI. New York: Pfizer Labs; 2011 [Accessed June 14, 2022].

  19. Zhou L, Wei X. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer. Front Immunol. 2021;12:701951.     

  20. Borodic GE, Hinkle DM. Reply Re: ”Drug-induced Graves disease from CTLA-4 receptor suppression“. Ophthalmic Plast Reconstr Surg. 2013;29(3):241.

  21. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(22 Pt 1):6681–6688.

  22. Robinson MR, Chan CC, Yang JC, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004;27(6):478–479.

  23. Gianni L, Panzini I, Li S, et al. International Breast Cancer Study Group (IBCSG) Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer. 2006;106(3):505–513.

  24. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol. 1993;111(3):350–356. 

  25. Fraunfelder FW, Fraunfelder FT. Interferon alfa-associated anterior ischemic optic neuropathy. Ophthalmology. 2011;118(2):408–411.e1.

  26. Oishi A, Miyamoto K, Kashii S, Yoshimura N. Retinopathy is not the only ocular symptom: myasthenia gravis in association with interferon therapy. Br J Ophthalmol. 2005;89(11):1542–1543.

Articole din ediţiile anterioare

SHORT REVIEWS | Ediţia 2 55 / 2021

Corelaţii între biomarkerii cancerului colorectal

Alin Radu, CSI Dr. Abil. Alexandru Grigorescu

Acest scurt review descrie principalii biomarkeri utilizaţi în cercetare şi în practica clinică pentru cancerul de colon.

24 aprilie 2021
SHORT REVIEW | Ediţia 1 54 / 2021

Radiomica şi radiogenomica în managementul cancerului bronhopulmonar – o scurtă recenzie

Liliana Eleonora Semenescu, Anda Crişan, Ciprian Camil Mireştean, Adina Mitrea, Irina Roxana Iancu, Dragoş Petru Teodor Iancu

Cancerul bronhopulmonar este principala cauză a mortalităţii prin cancer, diagnosticul tardiv fiind una dintre cauzele aso­cia­te cu decesul şi cu ...

24 martie 2021
ORIGINAL STUDY | Ediţia 3 / 2016

Studiul erorilor diagnostice și terapeutice corelate cu studiul markerilor tumorali cu impact în prognosticul pacienților cu cancer localizat la cap și gât

Ioan Andrei, Anda Crişan, Florinel Bădulescu, Michael Schenker

Introducere. Alegerea protocolului de tratament pentru pa­cienții cu carcinoame ale sferei ORL stadii avansate locoregional, rămâne o discuție desc...

07 martie 2017
CANCERUL DE SÂN | Ediţia 1 / 2016

Factori de prognostic în cancerul de sân triplu negativ

Silvia Ilie, Inga Botnariuc, Oana Trifănescu, Rodica ANGHEL, Xenia Bacinschi

Cancerul de sân triplu negativ (CSTN) este o boală agresivă chiar și în stadiile inițiale. Există o rată de recidivă de 30% în primii 5 ani în stad...

24 martie 2017